Condition
Pioglitazone
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03646292Phase 4Completed
Antidiabetic Drugs for Steatotic Liver Disease
NCT03566225Early Phase 1CompletedPrimary
Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome
NCT01309854Phase 1Completed
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
NCT01258322Not ApplicableCompleted
Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients
Showing all 4 trials